Study of Double-positive Circulating Cells in Various Metastatic Cancers Before Treatment

What this Trial Is About

Researchers are studying patients with metastatic cancers across nine different types to detect double-positive circulating cells in the blood using two different analysis methods. This pilot study aims to measure the presence of these cells before patients start any anti-cancer treatment, regardless of treatment line. The study enrolls patients treated at IUCT-O or other institutions and is led by Institut Claudius Regaud. Participants provide a blood sample of approximately 30 milliliters before beginning their metastatic cancer treatment. The blood samples are analyzed by flow cytometry for all patients, combined with either Parsotix4 or CellSearch4 analysis depending on the cancer type. The study includes nine cancer cohorts, each assigned to one of the analysis methods, and enrolls a total of 450 patients. Each participant is involved for one day to provide the blood sample, with no further treatment or follow-up required. Researchers evaluate the rate of patients with circulating double-positive cells detected by at least one of the two methods, as well as rates detected by each individual method. The primary outcome is assessed one year after the last patients last visit, focusing on the detection of these circulating cells as a tumor marker.

Research of Double-positive Circulating Cells (Tumor Marker / CD45+) in Several Types of Metastatic Cancers